
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc is demonstrating robust growth in its customer base, particularly with its Auryon product line in both the office-based labs (OBL) and hospital settings, contributing positively to the average selling price (ASP). The company is achieving a notable gross margin improvement of 52.5%, driven by its manufacturing initiatives scheduled for completion in January 2026 and a favorable revenue mix shift towards higher Med-Tech sales. Management's confidence in ongoing product demand is supported by new customer acquisitions, increased utilization in existing accounts, and successful price increases, indicating a sustainable growth trajectory.
Bears say
AngioDynamics Inc. faces significant financial challenges, as management has projected $4 million to $6 million in tariff headwinds that could impact overall profitability. Additionally, the company anticipates pressure on its inventory for the second half of 2026 due to rising raw material costs, which may further strain margins. While recent sales of NanoKnife disposables exceeded expectations, the reliance on capital sales raises concerns about long-term disposable demand sustainability.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares